Atrium Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeted therapeutics for cardiovascular diseases. Lead program ATR 1072 is being advanced for PRKAG2 syndrome, a rare genetic cardiac condition.
Company Info
Upcoming Milestones & Key Dates
Phase 1 trial initiation for ATR 1072
Clinical Development Pipeline
Recent News
/PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart,...
Leadership Team
CEO
Chief Scientific Officer
Chief Medical Officer
Careers & Job Openings